NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.
•EurekAlert
AI Analyzes 66,000 MRI Scans to Map Body Composition Risks
Researchers used AI to analyze over 66,000 whole-body MRI scans, creating a detailed body composition reference map linked to health risks.